Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin DeJesus

Showing results (131-140 of 154) with videos related to

Pageof 16
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2010
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analysesJeffrey L Lennox, Edwin Dejesus, Daniel S Berger, et al.
The New England Journal of Medicine|May 11, 2022
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionSorana Segal-Maurer, Edwin DeJesus, Hans-Jurgen Stellbrink, et al.
Infectious Diseases and Therapy|September 15, 2024
A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist VesatolimodSharon A Riddler, Constance A Benson, Cynthia Brinson, et al.
Lancet (London, England)|December 4, 2014
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trialMark Sulkowski, Christophe Hezode, Jan Gerstoft, et al.
The Lancet. HIV|June 7, 2020
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trialsChloe Orkin, Edwin DeJesus, Paul E Sax, et al.
The Lancet. Infectious Diseases|November 6, 2015
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority studyAnthony Mills, Jose R Arribas, Jaime Andrade-Villanueva, et al.
Lancet (London, England)|January 16, 2010
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsJoseph J Eron, Benjamin Young, David A Cooper, et al.
Science Translational Medicine|June 24, 2021
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapyDevi SenGupta, Cynthia Brinson, Edwin DeJesus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2020
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1Sharon A Riddler, Michael Para, Constance A Benson, et al.
Lancet (London, England)|April 20, 2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trialsPaul E Sax, David Wohl, Michael T Yin, et al.
Pageof 16

Showing results (131-140 of 154) with videos related to

Sort By:
Pageof 16
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2010
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analysesJeffrey L Lennox, Edwin Dejesus, Daniel S Berger, et al.
The New England Journal of Medicine|May 11, 2022
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionSorana Segal-Maurer, Edwin DeJesus, Hans-Jurgen Stellbrink, et al.
Infectious Diseases and Therapy|September 15, 2024
A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist VesatolimodSharon A Riddler, Constance A Benson, Cynthia Brinson, et al.
Lancet (London, England)|December 4, 2014
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trialMark Sulkowski, Christophe Hezode, Jan Gerstoft, et al.
The Lancet. HIV|June 7, 2020
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trialsChloe Orkin, Edwin DeJesus, Paul E Sax, et al.
The Lancet. Infectious Diseases|November 6, 2015
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority studyAnthony Mills, Jose R Arribas, Jaime Andrade-Villanueva, et al.
Lancet (London, England)|January 16, 2010
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsJoseph J Eron, Benjamin Young, David A Cooper, et al.
Science Translational Medicine|June 24, 2021
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapyDevi SenGupta, Cynthia Brinson, Edwin DeJesus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2020
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1Sharon A Riddler, Michael Para, Constance A Benson, et al.
Lancet (London, England)|April 20, 2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trialsPaul E Sax, David Wohl, Michael T Yin, et al.
Pageof 16